)
)
)
Oban Biopharma
Oban BioPharma, Inc. is focused on computational and AI-assisted approaches to discover next-generation allosteric/biased oral GPCR therapeutics for CNS and metabolic diseases. In CNS, Oban is advancing a series of proprietary, orally active, muscarinic M4 receptor Ago-PAMs for neuropsychiatric and neurological indications. Lead compounds exhibit dose-dependent activity in validated animal models of schizophrenia/psychosis comparable to the non-selective muscarinic agonist, xanomeline (COBENFY™ - FDA-approved, 2024). IND-enabling studies in progress.
In the metabolic area, Oban has identified a highly conserved allosteric pocket present across all the major metabolic GPCRs, including GLP-1, GIP, Glucagon and amylin receptors. We are targeting this site for the development of a novel class of small molecules; pan-metabolic multimodal agonists that possess intrinsic agonism (direct activation) combined with positive allosteric modulator (PAM) activity across multiple receptors.
Address
StamfordConnecticut
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)